485F US Highway One South
Suite 210
Iselin, NJ 08830
tel. 732.596.0276
fax 732.647.1235
Davy James
Group Editorial Director
djames@mjhlifesciences.com
Andrew Studna
Editor
astudna@mjhlifesciences.com
Michael Christel
Group Managing Editor
mchristel@mjhlifesciences.com
Miranda Schmalfuhs
Group Social Media Editor
mschmalfuhs@mjhlifesciences.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.